Any experience with this?
Desmopressin and Other Synthetic Vasopressin Analogues in Cancer Treatment
Desmopressin (DDAVP) is a well tolerated and convenient haemostatic agent that can be used in a number of clinical conditions with bleeding diathesis. It has several effects on the haemostatic system, causing endogenous release of coagulation factor VIII, von Willebrand factor and tissue-type plasminogen
activator, among others. In this review we present a growing body of evidence showing that DDAVP treatment may impair spread of cancer cells and contribute to encapsulation of tumour tissue. Our data in preclinical animal models suggest a potential application of DDAVP in the perioperative management of aggressive solid tumours. Novel vasopressin analogues with improved antitumor effects are currently
Found a case report where radiotherapy is blamed for tumor partial response:
Pituitary Chondrosarcoma: An Unusual Cause of a Sellar Mass Presenting as a Pituitary Adenoma
Review of the clinical, endocrinological, and radiological data suggested a probable nonfunctioning pituitary adenoma, and the patient underwent transsphenoidal removal of the mass.
On stopping the oral contraceptive she remained amenorrheic and was, thus, presumably gonadotropin deficient. The patient was, therefore, initiated on oral desmopressin (200 μg once a day), and she spontaneously restarted the oral contraceptive.
Histology revealed a well-differentiated cartilaginous tumor.
These findings were consistent with a well-differentiated (low grade) chondrosarcoma
A repeat MRI scan (data not shown) 3 weeks following the TSS showed a considerable amount of tissue still present in the suprasellar and left parasellar regions, but considerable reduction in the displacement and compression of the optic chiasm
In view of the nature of the tumor and the postoperative radiographic evidence of residual tumor, stereotactic“ radiosurgery” via multiarc radiotherapy from a linear accelerator was administered as a single dose 3 months following the original TSS (5)
Twelve months after the initial surgery the patient reported no further headaches and had no visual complaints.
However, MRI scanning of the pituitary 18 months after the original surgery (and 15 months after stereotactic radiotherapy) revealed further evidence of tumor shrinkage
The patient currently remains well on the oral contraceptive pill and desmopressin replacement therapy, with regular clinical assessment every 6 months and re-imaging every 12 months.
Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model
Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin. It has recently been demonstrated to inhibit tumor progression and metastasis in breast cancer models. Docetaxel is a chemotherapy agent for castrate-resistant prostate cancer (CRPC). In this study, the ability of CRPC cells to grow and develop in vivo tumors in an animal model was evaluated, in order to investigate the anti-tumor effect of desmopressin in combination with docetaxel. Materials and Methods: The CRPC cell line PC3 was used for orthotopic inoculation in male athymic nude mice. The mice were randomly assigned to one of the four treatment groups: Control, docetaxel, desmopressin or combination therapy. Following the last treatment, tumors were excised and measured. Blood samples were processed for CTC analysis. Results: Docetaxel treatment resulted in a significant reduction in tumor volume compared to control. The combination therapy resulted in even more significant reduction (31.2%) in tumor volume. There was a complete absence of CTCs in the combination group.
Conclusion: Our pilot study demonstrated an enhanced efficacy of docetaxel-based therapy in combination with desmopressin.
A patient with Ewing's sarcoma presented with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) (1). Plasma values for vasopressin were found to be over four times the normal values expected for the plasma osmolality. At postmortem examination, the arginine vasopressin concentration in the tumor tissue was ten times that of the plasma. These data suggest that Ewing's sarcoma may cause SIADH.
Was vasopressin consequence or cause?
@asafsh Very interesting one! And very good question! We can only try to answer that by diving deep into the field. Thank you for sharing these nice findings.
Thank you for reply. I feel incompetent to deal with it as it requires time (which is i am short of) to educate myself on human biology field in order to make necessary decisions. Of course i am trying to do my best amid negotiations with doctors, controlling drug yet many other things at the same time.
BTW, another alleviated vasopressin hormone level in animal sarcoma:
Syndrome of inappropriate antidiuretic hormone secretion in a dog with a histiocytic sarcoma
A 7-year-old female neutered Bernese mountain dog was presented in a semi-comatose state. Based on serum hypo-osmolality with inappropriate urine hyper-osmolality and urine sodium excretion, the dog was diagnosed with a syndrome of inappropriate antidiuretic hormone secretion secondary to a histiocytic sarcoma. This report describes the first case of this syndrome in a dog with histiocytic sarcoma.
Antidiuretic hormone (ADH), also known as vasopressin, is normally secreted in response to an increase in osmolality or decrease in arterial pressure or intravascular volume. However, ADH secretion is considerably more sensitive to small changes in osmolality than to similar changes in blood volume. If the extracellular fluid becomes too dilute (hypo-osmotic), ADH secretion is inhibited. Vasopressin increases the reabsorption of water in the collecting ducts of the kidneys and increases the permeability of the medullary collecting ducts to urea.
Intracranial desmoplastic small round cell tumor presenting as a suprasellar mass
A 27-year-old man was referred to the endocrinology clinic with a history of excessive tiredness, lethargy, and loss of libido. He had a medical history of depression and had been treated with fluoxetine.
A year later, the patient presented to the emergency department with worsening frontal headaches, drowsiness, and bitemporal hemianopia.
He was admitted to the neurosurgical unit, underwent a right frontoparietal craniotomy, and had near-total removal of the tumor
He developed central diabetes insipidus postsurgery and began treatment with desmopressin while continuing with hydrocortisone and levothyroxine replacement therapy.
An MRI scan obtained 4 months after craniotomy revealed rapid expansion of the suprasellar tumor remnant measuring 4.5 × 3.5 cm.
he patient's clinical condition deteriorated rapidly and he died 20 months after his initial presentation.
did i understand correctly that t4 hormone administered within levothyroxine replacement therapy helped for tumor relapse and growth?
Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy
Examination of the cancer genome atlas (TCGA) database, and analysis of human RCC tumor tissue microarrays, cDNA arrays and tumor biopsy samples demonstrated V2R expression and activity in clear cell RCC (ccRCC).
Tolvaptan and OPC31260 decreased RCC tumor growth by reducing cell proliferation and angiogenesis, while increasing apoptosis. In contrast, the V2R agonist dDAVP significantly increased tumor growth.
p.s. why didn't they try 5 dollar desmopressin along with newest costing 70K USD per year?
Just found summary about desmopressin in ReDO page:
My error - V2R agonist dDAVP is actually desmopressin. So previous article pointed to the increase in tumor growth upon its administration. So be cautious with it!